Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.66 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.66 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.66 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.66 |
| ▸ | FAP | Q12884 | 5/20 | 0.66 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10779357 | 0.82 | ACE (0.71) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL28827157 | 0.82 | ACE (0.71) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL30052872 | 0.82 | ACE (0.71) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL10779361 | 0.82 | ACE (0.71) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL7932223 | 0.81 | DPP4 (0.78) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL12938959 | 0.81 | DPP7 (0.49) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL17082336 | 0.81 | DPP4 (0.64) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL19981831 | 0.80 | DPP4 (0.61) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL3092652 | 0.79 | DPP4 (1.00) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL7938765 | 0.79 | DPP4 (1.00) | DPP4DPP8DPP7DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063719-A1 | Methods for treating diabetes | POINT THERAPEUTICS, INC. (US) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063719-A1 | Methods for treating diabetes | IAPP, SLC5A2, SLC2A3 | DPP4 5/4885DPP8 51/4885DPP7 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.